Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Alpha-1 antitrypsin: now available, but do we need it?Russi EWSwiss Med Wkly 2008[Apr]; 138 (13-14): 191-6Severe alpha1-antitrypsin (AAT) deficiency is the best characterised genetic risk factor for the development of emphysema. AAT has a wide spectrum of antiprotease activity and its primary function is inhibition of neutrophil elastase in the lung. Smokers with this genetic defect develop severe impairment in their fifth to sixth decade of life. Intravenous administration of human AAT is well tolerated and has been shown to increase the levels of AAT in the alveolar lining fluid of individuals with this deficiency. In contrast to the proof of the biochemical effectiveness of augmentation treatment, the favourable clinical effect of AAT on pulmonary function, emphysema progression, morbidity and survival has not been persuasively demonstrated by prospective controlled clinical trials and remains controversial.|Humans[MESH]|Infusions, Intravenous[MESH]|Leukocyte Elastase/*antagonists & inhibitors[MESH]|Pulmonary Disease, Chronic Obstructive/physiopathology[MESH]|Pulmonary Emphysema/drug therapy/*physiopathology[MESH]|Smoking/adverse effects[MESH]|Trypsin Inhibitors/pharmacology/*therapeutic use[MESH]|alpha 1-Antitrypsin Deficiency/*drug therapy[MESH]|alpha 1-Antitrypsin/administration & dosage/pharmacology/*therapeutic use[MESH] |